Rubicon Research Ltd.

NSE: RUBICON | BSE: 544578

Expensive Star

Download real time

1655.10 58.80 (3.68%)

640.8K NSE+BSE Volume

High volume today

NSE 11 Aug, 2026 3:31 PM (IST)

27,397.2

Market Cap

High in industry

Board Meeting

The next board meeting for Rubicon Research is on 14 Aug 2026 for the purpose of Quarterly Results See details

Rubicon Research Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RUBICON, BSE:544578 Rubicon Research Ltd.

Search Inside the pdf :

Rubicon Research Ltd.

30 May 2026

1655.10

3.68%

Another quarter, another beat: The compounder delivers

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered another outstanding quarter, beating revenue, EBITDA, and PAT estimates by 4%, 11%, and 15%, respectively.

Rubicon Research has gained 73.16% in the last 3 Months

Rubicon Research Ltd.

15 Apr 2026

1655.10

3.68%

Arinna acquisition: Unlocking distribution moat and domestic growth engine

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) aims to make inroads into the central nervous system (CNS) therapy in India’s branded market (DF) through Arinna Lifescience (Arinna).

Rubicon Research has gained 109.37% in the last 6 Months

Rubicon Research Ltd.

18 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading at high day volume of 565.2K.

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 241.26% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 109.37% in the last 6 Months

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Number of FII/FPI investors increased from 56 to 68 in Jun 2026 qtr.

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 15.63% in the last 1 Month

Rubicon Research Ltd.

13 Nov 2025

1655.10

3.68%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 15.63% in the last 1 Month

Rubicon Research Ltd.

31 Oct 2025

1655.10

3.68%

Gains in the gale

Buy: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).